Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to “Buy” at D. Boral Capital

D. Boral Capital upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a buy rating in a report published on Monday, Marketbeat reports. They currently have $9.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Trading Up 6.3 %

Shares of CTXR opened at $3.91 on Monday. The company’s 50 day simple moving average is $5.63 and its 200-day simple moving average is $12.03. Citius Pharmaceuticals has a 12-month low of $2.44 and a 12-month high of $26.75. The firm has a market cap of $28.27 million, a PE ratio of -0.65 and a beta of 1.48.

Hedge Funds Weigh In On Citius Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Citius Pharmaceuticals during the 3rd quarter worth $50,000. Geode Capital Management LLC lifted its position in Citius Pharmaceuticals by 14.1% in the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after purchasing an additional 232,656 shares during the period. XTX Topco Ltd purchased a new stake in Citius Pharmaceuticals in the 3rd quarter valued at approximately $47,000. Miller Investment Management LP increased its position in Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the period. Finally, Arkadios Wealth Advisors raised its stake in shares of Citius Pharmaceuticals by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after buying an additional 50,000 shares in the last quarter. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.